371 related articles for article (PubMed ID: 19404661)
1. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).
Konstantinidis L; Mameletzi E; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1165-71. PubMed ID: 19404661
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.
Parodi MB; Iacono P; Menchini F; Sheth S; Polini G; Pittino R; Bandello F
Acta Ophthalmol; 2013 May; 91(3):267-73. PubMed ID: 21951313
[TBL] [Abstract][Full Text] [Related]
3. Ranibizumab for retinal angiomatous proliferation.
Rouvas AA; Papakostas TD; Ladas ID
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1719-20. PubMed ID: 19669654
[No Abstract] [Full Text] [Related]
4. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.
Lai TY; Chan WM; Liu DT; Lam DS
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1877-80. PubMed ID: 17901972
[TBL] [Abstract][Full Text] [Related]
5. Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation.
Viola F; Mapelli C; Villani E; Tresca Carducci F; Vezzola D; Ratiglia R
Eye (Lond); 2010 Aug; 24(8):1344-51. PubMed ID: 20339389
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.
Meyerle CB; Freund KB; Iturralde D; Spaide RF; Sorenson JA; Slakter JS; Klancnik JM; Fisher YL; Cooney MJ; Yannuzzi LA
Retina; 2007; 27(4):451-7. PubMed ID: 17420697
[TBL] [Abstract][Full Text] [Related]
7. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.
Hufendiek K; Hufendiek K; Panagakis G; Helbig H; Gamulescu MA
Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.
Konstantinidis L; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Mar; 247(3):311-8. PubMed ID: 19043731
[TBL] [Abstract][Full Text] [Related]
9. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.
Introini U; Torres Gimeno A; Scotti F; Setaccioli M; Giatsidis S; Bandello F
Graefes Arch Clin Exp Ophthalmol; 2012 Sep; 250(9):1283-92. PubMed ID: 22350060
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy.
Konstantinidis L; Mantel I; Zografos L; Ambresin A
Eur J Ophthalmol; 2010; 20(5):955-8. PubMed ID: 20306440
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.
Ghazi NG; Knape RM; Kirk TQ; Tiedeman JS; Conway BP
Retina; 2008 May; 28(5):689-95. PubMed ID: 18463511
[TBL] [Abstract][Full Text] [Related]
12. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.
Seidel G; Werner C; Weger M; Steinbrugger I; Haas A
Acta Ophthalmol; 2013 Sep; 91(6):e482-5. PubMed ID: 23786546
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.
Reche-Frutos J; Calvo-Gonzalez C; Pérez-Trigo S; Fernandez-Perez C; Donate-Lopez J; Garcia-Feijoo J
Eur J Ophthalmol; 2011; 21(6):783-8. PubMed ID: 21484755
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.
Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB
Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III.
Montero JA; Fernandez MI; Gomez-Ulla F; Ruiz-Moreno JM
Eur J Ophthalmol; 2009; 19(3):448-51. PubMed ID: 19396793
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study.
Rouvas A; Petrou P; Vergados I; Pechtasides D; Liarakos V; Mitsopoulou M; Ladas I
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1609-16. PubMed ID: 19609550
[TBL] [Abstract][Full Text] [Related]
18. [Anti-VEGF treatment for retinal angiomatous proliferation].
Wolf A; Kook D; Kreutzer T; Gandorfer A; Haritoglou C; Kampik A; Ulbig M
Ophthalmologe; 2008 Sep; 105(9):845-51. PubMed ID: 18607601
[TBL] [Abstract][Full Text] [Related]
19. Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review.
Mahmood S; Kumar N; Lenfestey PM; Murjaneh S; Heimann H; Harding SP
Eye (Lond); 2009 Mar; 23(3):530-5. PubMed ID: 18425070
[TBL] [Abstract][Full Text] [Related]
20. [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].
Lommatzsch A; Heimes B; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Ophthalmologe; 2011 Mar; 108(3):244-51. PubMed ID: 20571805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
